Phase 2 Trials
LSD Therapy
LSD (lysergic acid diethylamide) is being researched for anxiety disorders and generalized anxiety. Definium Therapeutics (formerly MindMed) is leading Phase 2 trials with their MM-120 formulation.
50Clinical Trials
1Companies
0Legal States
FDA StatusPhase 2 Trials
Legal PathwayFDA approval pathway (federal)
Also Known Aslysergic acid diethylamide, acid, MM120
Legal Status by State
View full legal tracker →Legal
Decriminalized
Pending
No Legislation
Clinical Trials
13 trials currently recruiting
Phase 118
Phase 211
Phase 34
Unknown·N/A·LSD
Effect of a Low Starch Diet in Patients With Ankylosing Spondylitis
Universidade do Porto
SpondyloarthritisAnkylosing Spondylitis
Unknown·N/A·LSD
Investigating Lysosomal Storage Diseases in Minority Groups
O & O Alpan LLC
Lysosomal Storage DisordersGaucher DiseaseFabry Disease+2 more
Recruiting·Phase 3·LSD
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)
Definium Therapeutics US, Inc.
Generalized Anxiety Disorder
Completed·Phase 4·Other
Milrinone Versus Dobutamine in Critically Ill Patients
Ottawa Heart Institute Research Corporation
Low Cardiac Output SyndromeCardiogenic ShockAcute Coronary Syndrome+1 more
Completed·Phase 2·LSD
Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety
Multidisciplinary Association for Psychedelic Studies
Anxiety
Completed·N/A·LSD
The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers
Psychiatric University Hospital, Zurich
Healthy
Companies & Research
Organizations developing LSD-based therapies